Ebru Boslem


  • Monash Institute of Pharmaceutical Sciences, 399 Royal Parade, 404

    3052 Parkville


Accepting PhD Students

PhD projects

Novel drug targets for non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma


Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile


Ebru Boslem is a research officer in the Febbraio lab currently investigating the cellular mechanisms behind the reversal of non-alcoholic steatohepatitis (NASH) and prevention of hepatocellular carcinoma in the MuP-uPA mouse model of NASH. Previously in her role as Jenna Goggins Fellow at Sydney based biotech company, EnGeneIc, she was part of the team that characterised the immune response to a new generation of cancer cyto-immuno-therapy created from bacterially derived nanocells. During her time as post-doctoral researcher at the Garvan Institute of Medical Research in Sydney, she characterised mechanisms of lipid-induced apoptosis and pancreatic beta cell failure in the context of Type 2 diabetes. In her role as Young Garvan fellow, Ebru spoke at numerous public events including Garvan tours and public seminars to communicate the Institute's research and facilitated stakeholder meetings. Ebru received her PhD in 2011 from the Garvan/UNSW, working in Professor Trevor Biden's lab on pancreatic beta cell apoptosis.

Research interests

  • cancer immunology
  • mechanistic cell biology behind cancer cell growth and death
  • streamlining AI to probe big data for drug dicovery

Education/Academic qualification

Medicine, PhD, University of New South Wales

Feb 2007May 2011

Award Date: 9 May 2011

Research area keywords

  • Cancer Immunology
  • Cancer Cell Biology
  • non-alcoholic fatty liver disease
  • hepatotoxicity


Recent external collaboration on country level. Dive into details by clicking on the dots or
If you made any changes in Pure these will be visible here soon.